key: cord-1030179-gkku88os
authors: Drożdżal, Sylwester; Rosik, Jakub; Lechowicz, Kacper; Machaj, Filip; Szostak, Bartosz; Przybyciński, Jarosław; Lorzadeh, Shahrokh; Kotfis, Katarzyna; Ghavami, Saeid; Łos, Marek J.
title: An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
date: 2021-12-09
journal: Drug Resist Updat
DOI: 10.1016/j.drup.2021.100794
sha: 19a30e64d6e5b2ba0f65452ad039bf5f4cd0f932
doc_id: 1030179
cord_uid: gkku88os

The COVID-19 pandemic is one of the greatest threats to human health in the 21(st) century with more than 257 million cases and over 5.17 million deaths reported worldwide (as of November 23, 2021. Various agents were initially proclaimed to be effective against SARS-CoV-2, the etiological agent of COVID-19. Hydroxychloroquine, lopinavir/ritonavir, and ribavirin are all examples of therapeutic agents, whose efficacy against COVID-19 was later disproved. Meanwhile, concentrated efforts of researchers and clinicians worldwide have led to the identification of novel therapeutic options to control the disease including PAXLOVID™ (PF-07321332). Although COVID-19 cases are currently treated using a comprehensive approach of anticoagulants, oxygen, and antibiotics, the novel Pfizer agent PAXLOVID™ (PF-07321332), an investigational COVID-19 oral antiviral candidate, significantly reduced hospitalization time and death rates, based on an interim analysis of the phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. The scheduled interim analysis demonstrated an 89% reduction in risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset (primary endpoint). However, there still exists a great need for the development of additional treatments, as the recommended therapeutic options are insufficient in many cases. Thus far, mRNA and vector vaccines appear to be the most effective modalities to control the pandemic. In the current review, we provide an update on the progress that has been made since April 2020 in clinical trials concerning the effectiveness of therapies available to combat COVID-19. We focus on currently recommended therapeutic agents, including steroids, various monoclonal antibodies, remdesivir, baricitinib, anticoagulants and PAXLOVID™ summarizing the latest original studies and meta-analyses. Moreover, we aim to discuss other currently and previously studied agents targeting COVID-19 that either show no or only limited therapeutic activity. The results of recent studies report that hydroxychloroquine and convalescent plasma demonstrate no efficacy against SARS-CoV-2 infection. Lastly, we summarize the studies on various drugs with incoherent or insufficient data concerning their effectiveness, such as amantadine, ivermectin, or niclosamide.

virus. Patients were randomly assigned (1:1:1) to receive a placebo, 2.4 g of REGN-COV2, or 8 .0 g of REGN-COV2 and were prospectively characterized at baseline for the endogenous immune response against SARS-CoV-2 (serum antibody-positive or serum antibodynegative). Key endpoints included the time-weighted average change in viral load from baseline (day 1) through day 7 and the percentage of patients with at least one COVID-19related co-morbidity who attended a clinic visit through day 29. Data from 275 patients are reported; the least-squares mean difference (the combined REGN-COV2 dose groups vs. the placebo group) in the time-weighted average change in viral load from day 1 through day 7 was -0.56 log10 copies per milliliter (95% CI: -1.02 --0.11) among patients who were serum antibody-negative at baseline and -0.41 log10 copies per milliliter (95% CI: -0.71 --0.10) in the overall trial population. In this interim analysis, REGN-COV2 reduced viral load, and to a greater extent in patients whose immune response had not yet been initiated or who had a high viral load at baseline 36 .

Tocilizumab (RoActemra, Roche Pharma AG) is a recombinant humanized IgG1 mAb that binds specifically to both soluble and membrane-bound receptors for IL-6 (sIL-6R and mIL-6R), thereby inhibiting this signaling pathway, and reducing the pro-inflammatory effect of IL-6 37 . In their dissertation, Malgie et al., reviewed and performed a meta-analysis of observational studies evaluating the effect of tocilizumab on COVID-19 patient mortality.

The authors included 10 studies related to the use of tocilizumab, totaling 1,358 patients, with nine out of ten studies found to be of high quality. The meta-analysis showed that the mortality in the tocilizumab group was lower than in the control group [RR=0.27 (95% CI: 0.12 -0.59); the risk difference=12% (95% CI: 4.6% -20%)]. With only a few studies available, no difference in side effects has been observed. Mortality was 12% lower in the group of patients who received tocilizumab compared to those who did not, although these results require confirmation in randomized controlled trials (RCTs) 38 .

In another review by Arthur et al., researchers analyzed 10 RCTs evaluating the effect of tocilizumab in COVID-19 in which they allocated patients to two groups. The control group received the standard care, while the treatment group was comprised of patients who received tocilizumab in addition to standard care; the primary outcome was 28 to 30-day mortality.

Secondary endpoints included progression to severe disease, defined as the need for mechanical ventilation, intensive care unit (ICU) admission, or complex disease. Out of 6,493 patients, 3,358 (52.2%) were allocated to tocilizumab. The results demonstrated that tocilizumab use was associated with decreased mortality [24.4% vs. 29.0%; odds ratio (OR)=0.87 (95% CI: 0.74 -1.01); p=0.07]. Tocilizumab did reduce the need for mechanical ventilation and was associated with an advantage in the composite secondary endpoint, but did not reduce the number of ICU admissions 39 .

However, the results of a phase 3 trial were contradictory. The NCT04320615 study described by Rosas et al., did not present a difference between tocilizumab and placebo groups [mortality at day 28 was 19.7%the tocilizumab group and 19.4%the placebo group (95% CI = -7.6 to 8.2; p = 0.94)] 40 . A Study authors suggests considering the use of tocilizumab in hospitalized COVID-19 patients with hypoxia and laboratory signs of significant inflammation.

Remdesivir is an adenosine analogue that is metabolized to its active metabolite, remdesivir triphosphate. Remdesivir triphosphate is a structural analog of adenosine triphosphate (ATP) and competes with the natural substrate for the incorporation by RNA polymerase into nascent viral RNA, which results in delayed chain termination during replication and consequently inhibition of viral replication (Fig. 4) 41 . however, there was no significant difference on day 28 42 

considering the use of remdesivir in patients with confirmed SARS-CoV-2 infection during the period of viral replication (i.e., not later than 5-7 days from the onset of the first symptoms of the disease) in patients with documented pneumonia and peripheral blood oxygen saturation (SpO2) ≤ 94% (when breathing atmospheric air).

Baricitinib is a selective inhibitor of janus activated kinase 1 (JAK1) and janus activated kinase 2 (JAK2), the two of which mediate signaling for cytokines and growth factors involved in hematopoiesis, inflammation, and the immune response. It modulates intracellular signaling by partially inhibiting JAK1 and JAK2 enzymatic activity, thereby reducing phosphorylation and activation of STAT proteins. Baricitinib inhibits the induction of IL-6 in a dose dependent manner while also reducing the serum concentration of C-reactive protein (CRP) 43 .

In a multi-center study, the beneficial impact of baricitinib was tested in COVID-19 patients with moderate pneumonia 44 . At baseline, 113 patients were included in the baricitinib-arm, and 78 in the control-arm. The results indicate that the 2-week case fatality rate was significantly lower in the baricitinib-arm compared with controls [0% (0/113) vs. 6.4% (5/78) (p=0.010; 95% CI: 0.0000 -0.4569)]. ICU admission was necessary in 0.88% (1/113) patients in the baricitinib-arm compared to the 17.9% (14/78) in the control-arm in week 1 (p=0.019; 95% CI: 0.0092 -0.6818), and week 2 (p<0.0001; 95% CI: 0.0038 -0.2624).

Discharge rate was significantly higher in the baricitinib-arm at week 1 [9.7% (11/113) 

Tofacitinib is a potent and selective inhibitor of the JAK family of kinases. Tofacitinib has been shown to inhibit the activity of JAK1, JAK2, and JAK3, and to a lesser extent tyrosineprotein 2 kinases (TyK2). In human cells, tofacitinib inhibits the signaling of heterodimeric cytokine receptors which bind JAK3 and/or JAK1, and that possess greater functional selectivity than that of cytokine receptors that signal through JAK2 kinase pairs. Inhibition of JAK1 and JAK3 kinases by tofacitinib attenuates interleukin signaling (IL-2, IL-4, IL-6, IL-7, J o u r n a l P r e -p r o o f IL-9, IL-15, and IL-21), as well as interferon type I and type II signaling, resulting in modulation of the immune response 46 .

Guimarães et al., assessed the efficacy and safety of tofacitinib in patients hospitalized for coronavirus pneumonia. Two groups of adult patients (n=289 in total) with COVID-19 pneumonia were randomized in a 1:1 ratio, receiving either 10 mg of tofacitinib or a placebo twice daily for up to 14 days or until hospital discharge. Efficacy was assessed after 28 days and examined the death or respiratory failure rate. Furthermore, 89.3% of patients were receiving glucocorticoids during their hospitalization. The cumulative incidence of death or respiratory failure up to day 28 was 18.1% in the tofacitinib group and 29.0% in the placebo group (hazard ratio (HR)=0.63; 95% CI: 0.41 -0.97; p=0.04). By day 28, death from any cause had occurred in 2.8% of patients in the tofacitinib group and in 5.5% of patients in the placebo group (HR=0.49; 95% CI: 0.15 -1.63). The authors summarized the study by stating that among patients hospitalized with COVID-19 pneumonia, tofacitinib led to a decrease in the risk of death or respiratory failure by day 28 in comparison with a placebo 47 . According to the authors, the use of tofacitinib in hospitalized patients diagnosed with COVID-19 may be considered.

The endoplasmic reticulum (ER) is the site of both protein translation and protein folding 48 .

However, if the protein load that is shuffled into the ER exceeds its folding capacity, there is an accumulation of unfolded proteins which triggers the ER stress response, and activates a pathway known as the unfolded protein response (UPR) 49 . UPR aims to improve ER folding capacity by reducing global protein synthesis and inducing molecular chaperone expression 50 .

However, if ER stress is not resolved, UPR directs the cell towards programmed cell death 51 .

Multiple studies have shown that CoV replication in the cytoplasm directly induces ER stress, leading to the activation of UPR in infected cells. As an intricate interplay between UPR and the inflammatory response, apoptosis, autophagy, and innate immunity exists, ER stress can significantly affect the patient's antiviral response 52,53 . Recent evidence suggests that upon coronavirus infection, ER stress and UPR are induced by excessive synthesis, modification, and folding of viral proteins that results in ER membrane restructuring and its subsequent exhaustion due to continued formation of new virions 54,55 . Moreover, some members of the coronaviridae family are capable of utilizing certain aspects of UPR to overcome protein translation shutdown and ensure the production of their own proteins 56 . Moreover, in severe COVID-19 cases, hypoxemia may trigger a response from both mitochondria and ER, which is directed towards restoring oxygen level and promoting cell survival 57 . However, if this state persists, the role of UPR would then be altered from pro-survival to induction of apoptosis, which is possibly one of the molecular causes of organ damage in COVID-19 48 .

Unsurprisingly, multiple therapeutic drug candidates for COVID-19 infection are autophagy modulators. It is therefore possible that the beneficial effect of these drugs is perhaps due to the over-accumulation of autophagosomes that can induce apoptotic cell death of virally infected cells 58 . Further research exploring CoV-induced UPR could help identify novel therapeutic targets that are based directly on the pathogenesis of the disease.

Studies exploring UPR reveal that the inositol-requiring enzyme 1 (IRE1) axis is involved in the regulation of the secretome of cells via production of spliced XBP 59 In another study, SARS-CoV activated the protein kinase R-like reticulum kinase (PERK) arm of UPR, thereby increasing the phosphorylation of eukaryotic initiation factor 2 alpha (eIF2). As PERK activation suppresses type 1 interferon signaling, it could be a potential mechanism through which innate immunity is suppressed in CoV infected cells 60 . Therefore, PERK inhibitors could potentially aid in halting SARS-CoV-2 infection.

Paxlovid is a therapeutic combination consisting of two compounds: PF-07321332, an oral covalent 3CL protease inhibitor of SARS-CoV-2 and ritonavir, an inhibitor of HIV-1 and HIV-2 protease.

Ritonavir is also an inhibitor of cytochrome P450 3A and CYP2D6, thus inhibiting the metabolism of PF-07321332 and allowing the administration of a lower dose of the substance. In contrast, P-07321332 binds to the catalytic cysteine residue of CyS145 in all coronavirus proteases infecting humans. 61 In a recent study, the participants were randomized 1:1; half of which received paxlovid and the other half received placebo administered orally every 12 hours for five consecutive days. 62 The study revealed that patients who were treated within three days of symptom onset, 0.8% (3/389) of them who received paxlovid were admitted to hospital by day 28 after randomization, with no deaths. In comparison, 7% (27/385) of patients who received placebo were admitted to the hospital, with seven deaths. The statistical significance of these results was assessed as high (p < 0.0001). In subjects treated within five days of symptom onset, with 1% (6/607) in the paxlovid group taken by day 28 (no deaths) and 6.7% (41/612) in the placebo group (10 deaths)). Up to day 28, no deaths were reported in the paxlovid group as compared to 10 deaths (1.6%) in the placebo group. 62

The mechanism of action of molnupiravir (Lagevrio) is based on a novel approach to fighting viruses.

The compound is converted in the patient's body into a synthetic cytidine nucleoside. It then introduces errors into the genetic material of the viruses RNA as it replicates. The mutations lead to J o u r n a l P r e -p r o o f defective viral elements, hence neutralizing the pathogen, ultimately exerting an antiviral effect. 63 Among 202 participants of a recent study, significantly lower number of participants receiving 800 mg dose of molnupiravir (1.9%) were carried virus that could be isolated, as compared to placebo (16.7%) at day 3 (p = 0.02). At day 5, virus could not be isolated from any participants receiving 400 or 800 mg molnupiravir, versus 11.1% of those receiving placebo (p = 0.03). Molnupiravir was generally well tolerated, with similar adverse events across all groups. 64 patients from nine studies, as well as individual patient data for 895 patients from six of the analyzed studies. 67 Eight trials were observational studies, and one was a randomized controlled trial. The data taken into account were age, comorbidities, baseline partial pressure of oxygen in arterial blood, the 

Sotrovimab (Xevudy, also known as VIR-7831 and GSK4182136) is a monoclonal antibody with an activity against COVID-19. Sotrovimab was designed to attach to S protein of SARS-CoV-2. When it binds to S protein, the ability of the virus to enter the cells of the body are reduced. This is expected to reduce both the severity of the disease and need for hospitalization in COVID-19. 68 One article reported that the drug was administered at a dose of 500 mg or placebo. The primary efficacy outcome was hospitalization exceeding 24 hours for any cause or death within 29 days of randomization. In this pre-specified interim analysis, which included an intention-to-treat population of 583 patients (291 in the sotrovimab group and 292 in the placebo group), 3 patients (1%) in the sotrovimab group, as compared with 21 patients (7%) in the placebo group, experienced disease progression leading to hospitalization or death (relative risk reduction, 85%; 97.24% confidence interval, 44 to 96; p=0.002).

In the placebo group, 5 patients were admitted to the ICU, including 1 who died by day 29. The safety assessment was performed in 868 patients (430 in the sotrovimab group and 438 in the placebo group).

The adverse events were reported in 17% of subjects in the sotrovimab group and 19% of those in the placebo group; serious adverse events were less common with sotrovimab than with placebo (in 2% and 6% of the patients, respectively). 69 J o u r n a l P r e -p r o o f

Tixagevimab and cilgavimab (Evusheld), two monoclonal antibodies have been designed to attach to the spike protein of SARS-CoV-2 at two different sites. By attaching to the spike protein, the medicine is expected to stop the virus from entering the body's cells and causing infection. Because the antibodies attach to different parts of the protein, using them in a combination may be more effective than using either of them alone. The results of a recent trial funded by Astra Zeneca met the primary endpoint, with a dose of 600 mg of AZD7442 given by intramuscular (IM) injection reducing the risk of developing severe COVID-19 or death (from any cause) by 50% compared to placebo in outpatients who had been symptomatic for seven days or less. The trial recorded 18 events in the AZD7442 arm (18/407) and 37 in the placebo arm (37/415). The LAAB was generally well tolerated in the trial. In a pre-specified analysis of participants who received treatment within five days of symptom onset, AZD7442 reduced the risk of developing severe COVID-19 or death (from any cause) by 67% compared to placebo, with nine events in the AZD7442 arm (9/253) and 27 in the placebo arm (27/251). 70 

During the early days of the COVID-19 pandemic, many scientists and physicians placed hope in hydroxychloroquine (HCQ) and other antimalarial drugs. Moreover, non-randomized studies describing the positive effects of this drug are cited more often than any subsequent randomized trials about its lack of clinical benefit or even harmful side-effects 71 . With time, the severity of adverse effects and long-term consequences of HCQ treatment were elucidated 29,72 . HCQ used both in monotherapy and in combination with azithromycin has been shown to increase the prevalence of a prolonged QTc as a side effect. An association with higher incidence of arrhythmias has not been demonstrated, although this is possibly due to underestimated reporting frequency 72 .

According to studies with a high level of certainty surrounding their evidence, HCQ does not reduce mortality in patients with COVID-19 73, 74 . Moreover, a meta-analysis performed by Axfors et al., showed that patients had an all-cause combined mortality OR of 1.11 for hydroxychloroquine (95% CI: 1.02 -1.20) 75 . The effect of pharmacological prophylaxis in COVID-19 has also been disputed. Bartoszko et al., showed that taking HCQ has practically no effect on hospital admission or mortality, but it significantly increased the incidence of side effects. A meta-analysis of the available RCTs demonstrated no positive effects of the drug, but instead the incidence of side effects increased [RR = 1.81 (95% CI: 1.36 -2.42); p < 0.05] 76 . The study authors, do not recommend the use of chloroquine and hydroxychloroquine for either post-exposure prophylaxis or the treatment of COVID-19.

Colchicine may play a role in reducing the symptoms of COVID-19, as it binds to b-tubulin hence blocking microtubule polymerization. This in turn affects the spindle, and therefore reduces the movement and degranulation of intracellular lysosomes and the release of lysozymes, chemoattractants, and lactic acid. It inhibits the phagocytosis of sodium urate crystals by leukocytes, and reduces the breakdown of leukocyte cell membranes through their mobilization, migration, and the ability to adhere 77 . It is characterized by anti-inflammatory effects achieved through a reduction of leukocyte migration, inhibition of endothelial adhesion, reduction in interleukin production, and cytokine storm prevention 78 . Colchicine is a powerful anti-inflammatory agent routinely used to treat gout, viral pericarditis, coronary artery disease, and familial Mediterranean fever. Golpour et al., in a meta-analysis analyzed the effect of colchicine on the treatment of COVID-19. Colchicine was shown to be responsible for reducing mortality and length of hospitalization, and may therefore be an effective therapeutic option to improve COVID-19 treatment 79 .

The concept of using convalescent plasma in the treatment of COVID-19 was enthusiastically received by clinicians, internationally. The premise was based on the theory that antibodies produced by convalescent patients would help the recipients' body combat the infection and improve their prognosis. The initial results were very promising, but the intervention group not only included COVID-19 patients, but also those with SARS, MERS, and influenza 80 

Amantadine hydrochloride, a synthetic tricyclic amine, is an antiviral drug known since the 1960s for the treatment of influenza A. It works by blocking M2 ion channels, inhibiting viral entry into cells, and inhibiting viral replication. 85 A model was proposed by Abreu et al., in which amantadine blocks viroportin E of the SARS-CoV-2 virus, preventing the release of genetic material into the host nucleus 86 . It was J o u r n a l P r e -p r o o f also shown to inhibit the replication of the virus in vitro, however, this occurred only at a concentration higher than that achievable with oral supplementation 87 .

When discussing amantadine, it is worth mentioning the neurological complications of COVID-19, i.e. agitation, myoclonus, abulia, alogy 88 , brain fog, and chronic fatigue 89 . Studies are emerging to assess the effects of amantadine on alleviating theses neurological symptoms.

It has been suggested that amantadine can potentially help in the treatment of catatonia, especially in patients with contraindications to benzodiazepines due to respiratory failure 90 .

Additionally, amantadine may support the treatment of depressive disorders 91 . The study authors did not recommend the routine use of amantadine in COVID-19 patients limiting its use to a clinical trial.

Ivermectin is one of the most commonly used drugs to treat parasitic infections in humans as well as in animals in veterinary medicine. Its mechanism is based on the selective, positive allosteric modulation of glutamate chloride channels found in nematodes and insects. It acts by binding to these channels, leading to an influx of chloride ions, causing cell hyperpolarization and thus dysfunction. Moreover, at higher concentrations, ivermectin can also bind to GABA receptors 91 . Ivermectin is rapidly absorbed orally and has high liposome solubility. Moreover, it is metabolized in the liver (by the cytochrome P450 system) and almost exclusively excreted in feces 92 However, other studies did not report statistically significant differences in mortality 95 , length of hospitalization 96 and clinical endpoints, disease progression, recovery, the occurrence of symptoms 97 . The study authors did not recommend the routine use of ivermectin in COVID-19 patients, limiting its use to a clinical trial.

Niclosamide (NIC) is an oral chlorinated salicylanilide. In clinical practice, it is a drug used to treat tapeworm infections. Its mechanism of action is centered around decoupling the electron transport chain from ATP synthase, thereby abolishing ATP synthesis. When administered orally, NIC specifically induced the degradation of the androgen receptor variant V7 (AR-V7) via a proteasome-mediated pathway. This action decreased the expression of the AR variant, inhibiting its transcriptional activity and reducing the recruitment of AR-V7 into the prostate- conditions. Hence NIC achieved clinical benefits by freeing up hospital beds for more patients in a pandemic crisis 102 . The authors did not recommend the routine use of NIC in COVID-19 patients, limiting its use to a clinical trial.

Sarilumab (Kevzara) is a human monoclonal antibody that acts to inhibit the binding of IL-6 to its α receptor. This drug is approved for the treatment of adults with moderately to severely active rheumatoid arthritis. Due to sarilumab ability to inhibit both soluble and membranebound IL-6 receptor, it has the potential to exert a therapeutic effect in patients with SARS-CoV-2 infection 103 .

A study by Lescure et al., describes the effects of sarilumab in patients admitted to the hospital with severe or critical COVID-19. This was a phase 3 randomized, double-blind, placebo-controlled study on 416 patients allocated to 3 groups. Group one received a placebo, the second group received sarilumab at a dose of 200 mg and the third group received the drug at a dose of 400 mg. The authors concluded that the use of sarilumab was not effective in patients admitted to the hospital with COVID-19 and receiving oxygen supplementation. In patients with critical illness due to COVID-19, appropriately enhanced trials of targeted immunomodulatory therapies assessing survival as a primary endpoint, are suggested 104 .

In many environments, folk medicine plays an important role in the treatment of various diseases, especially those that people fear, or when conventional medicine is powerless or unable to propose effective treatment. This can be seen during the course of some cancers, and the beginning of the COVID-19 pandemic. Patients' questions often relate to Chinese 

Vitamin C has been used as a remedy for cold-like symptoms for years. Studies on animal models show that vitamin C reduces vascular permeability, improves blood circulation, and due to its antioxidant effect, reduces the amount of free radicals 112, 113 . Furthermore, there have been reports of vitamin C used in combination with hydrocortisone and thiamine to treat sepsis and acute respiratory distress syndrome, significantly reducing mortality 114 .

Gao et al., conducted a study in which vitamin C was administered at high doses to patients with COVID-19 (n=46) and compared them with standard treatment (n=30). The study showed a significant reduction in mortality and a lower need for respiratory support. Given the availability of vitamin C, there is a lack of large adequately powered studies confirming or contradicting the effectiveness of this supplement in treating COVID-19 115 It is also worth mentioning that zinc, one of the micronutrients, was postulated to be effective in the combat against COVID-19. It was shown that supplementation with zinc reduced mortality in pneumonia without increasing the risk of therapy failure 119 . Its role is to reduce oxidative stress and inflammation 120 14.0%; rate ratio=1.19 (95% CI: 0.92-1.55)]. This study showed that dexamethasone treatment resulted in a lower 28-day mortality in patients hospitalized for COVID-19 who were undergoing mechanical ventilation or oxygen therapy, but not for those patients who did not receive respiratory support 124 .

The results of the most recent trial pertaining the use of dexamethasone, the COVID 

Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA) inhibitors, are lipidlowering drugs that display pleiotropic effects. As acute respiratory distress syndrome (ARDS), the main cause of death from COVID-19, is caused by exaggerated inflammatory response, the immunomodulatory properties of statins have become of interest in the context of COVID-19 research, and have previously shown a beneficial effect in the treatment of autoimmune, inflammatory, and infectious diseases 135 . These agents could potentially limit the cytokine storm by blocking NF-κB and NLRP3 inflammasomes 136 . Moreover, statins also affect the cell cycle, even leading to its arrest, induce autophagy and apoptosis, which is likely to further limit viral replication 137 . However, the significance of the mechanism in which statins possibly increase SARS-CoV-2 virus entry by inducing ACE-2 expression is still not fully known 136, 138 .

The wide-spread use of statins has enabled the researchers to conduct large-scale retrospective studies amongst COVID-19 patients. Members of our team performed such a study of statintreated vs non-treated people, who were infected with SARS-CoV-2. However, data from a group of 150 patients, 75 of which received statins, failed to reach statistical significance.

However, these data have encouraged us to conduct larger retrospective analyses or even prospective studies 139 . A large retrospective study on 13,981 patients from China found an association between the statin use and lower risk of mortality 138 .

A meta-analysis of 4 studies showed that the use of statins is associated with a significantly reduced hazard for fatal or severe disease (pooled HR=0.70; 95% CI: 0.53-0.94), although these results based on 8,990 patients strongly highlight a need for prospective studies 140 .

The currently available data seems encouraging and suggests that in no case should the use of statins be abandoned during COVID-19 infection. However, it is too soon to include statins in the routine therapeutic plan for COVID-19 treatment 141 . Moreover, people, who start therapy with statins due to cardiovascular diseases during the pandemic should be aware that some of the potential side effects might mimic COVID-19. Muscle-related symptoms especially, are similar when comparing the side-effects of statins or viral infection 142 .

COVID-19 symptoms can, in some cases, persist for months. The virus can damage the lungs, heart and brain, which significantly increases the risk of long-term health issues. This group of conditions has been called post-COVID-19 syndrome or long COVID-19 143 . In general, they are considered to be the effects of COVID-19 that persist for more than four weeks after diagnosis 144 . SARS-CoV-2 can cause severe inflammation that is triggered by the immune system, which responds by increasing the rate of coagulation, which is triggered largely due to other systems in the body being affected by blood clots, such as the lungs, kidneys, liver, or J o u r n a l P r e -p r o o f heart. Moreover, COVID-19 can also weaken blood vessels and cause them to leak, which further contributes to the potential long-term complications affecting the kidneys and liver 145 .

The SARS-CoV-2 infection requires the cooperation of several essential systems to maintain homeostasis. The direct effect of SARS-CoV-2 hyperinflammation induces the production of endogenous compounds that promote the alteration of vascular hemostasis 146 . Furthermore, the release of pro-inflammatory and pro-thrombotic cytokines has a direct effect on blood coagulation. These factors result in disseminated intravascular coagulation and the formation of thromboembolic conditions that can affect various tissues, especially those which are more sensitive to ischemic processes, such as pulmonary, cardiovascular, and cerebrovascular tissues 145, 147 . The cardiopulmonary system especially is severely affected 148 . The lungs suffer from gradual functional failure, which is reflected by hypoxia and pathological findings 144, 149 .

Among the most common pathologies of the lung, respiratory failure, pulmonary thromboembolism, pulmonary embolism, pneumonia, pulmonary vascular damage, and postviral pulmonary fibrosis should be highlighted [150] [151] [152] . So far, there is no single, proper guideline for treating pulmonary complications after COVID-19. It has been suggested that physical exercise and appropriate rehabilitation, including breathing exercises, may help to resolve pulmonary symptoms 153 . In more severe cases, the use of opioids may reduce respiratory effort 154 . However, lung fibrosis may be a long-term complication. Due to the relatively short follow-up period from the first infection, the available data on this phenomenon is limited. Therefore, it is suggested that the treatment recommendations regarding idiopathic pulmonary fibrosis be followed. 152 There have been reports in the literature that the use of spironolactone during COVID-19 infection can prevent fibrosis 155 .

The most experienced cardiac complications include angina, acute coronary syndromes, and arrhythmias. The NICE recommendations point to the use of beta blockers in these cases [156] [157] [158] . Furthermore, remission of one complication, myocarditis, might depend on J o u r n a l P r e -p r o o f immunomodulatory effect 159 . Complications related to the nervous system following COVID-19 infection include loss of taste, smell and hearing, headaches, spasms, convulsions, confusion, visual disturbances, neuralgia, dizziness, disturbance of consciousness or delirium, nausea and vomiting, hemiplegia, ataxia, stroke, as well as cerebral hemorrhage [160] [161] [162] [163] [164] [165] .

According to Crook et al., chronic fatigue syndrome can be compared to the myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) so treatment may include cognitive behavioral therapy (CBT) and graded exercise therapy (GET) 153 . In the case of cognitive impairment, the so-called brain fog, apart from psychological support, methylphenidate, donepezil, modafinil, and memantine may also be helpful 153, 166, 167 . 168, 169 . In addition to kidney damage, the other system affected by complications from COVID-19 infection is the digestive system and liver. A meta-analysis of thirty-one studies examining the incidence of gastrointestinal symptoms in 4,682 patients found that diarrhea and anorexia were among the most significant gastrointestinal symptoms associated with COVID-19. In addition, it was observed that patients admitted to ICU or with high intensity were more likely to develop abdominal pain and increased hepatic inflammatory markers such as aspartate aminotransferase or alanine aminotransferase 170 .

One of the other potential long-term complications of COVID-19, due to long-term persistence of viral particles in organs, is interaction with autophagy machinery (DOI: J o u r n a l P r e -p r o o f 

Origin and evolution of pathogenic coronaviruses

The COVID-19 pandemic: a global health crisis

An Overview of Their Replication and Pathogenesis

Evolution patterns of SARS-CoV-2: Snapshot on its genome variants

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses

Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19)

COVID-19) Treatment Guidelines. National Institutes of Health

Fact Sheet for Healthcare Providers: Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab

Fact Sheet for Healthcare Providers: Emergency Use Authorization (EUA) of REGEN-COV (Casirivimab and Imdevimab)

Fact Sheet for Healthcare Providers: Emergency Use Authorization (EUA) of Sotrovimab

SARS-CoV-2 variants and ending the COVID-19 pandemic

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

Boosting immunity to COVID-19 vaccines

Waning Immunity after the BNT162b2 Vaccine in Israel

Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance -Eight U.S. Locations

Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis

CoV555, protects against SARS-CoV-2 infection in nonhuman primates

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

An EUA for sotrovimab for treatment of COVID-19

An EUA for casirivimab and imdevimab for COVID-19

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

The first interleukin-6-receptor inhibitor

Decreased Mortality in Coronavirus Disease

Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies

Tocilizumab in COVID -19 : a meta -analysis , trial sequential analysis , and meta -regression of randomized -controlled trials

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies

Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis. Infection

Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients

Regulation of stress responses and translational control by coronavirus

Unfolded protein response (UPR) integrated signaling networks determine cell fate during hypoxia

Autophagy and SARS-CoV-2 infection: A possible smart targeting of the autophagy pathway

Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy

The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor

Covid-19: UK becomes first country to authorise antiviral molnupiravir

Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2

Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv Prepr Serv Heal Sci

COVID-19: EMA recommends authorisation of two monoclonal antibody medicines

SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19

Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis

Bethesda (MD)

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial

A metaresearch study revealed susceptibility of Covid-19 treatment research to white hat bias: first, do no harm

QTc prolongation in COVID-19 patients treated with hydroxychloroquine , chloroquine , azithromycin , or lopinavir / ritonavir : A systematic review and meta-analysis

Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial

Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials

Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials

Prophylaxis against covid-19: living systematic review and network meta-analysis

Colchicine-Update on mechanisms of action and therapeutic uses

Colchicine and SARS-CoV-2: Management of the hyperinflammatory state

The effectiveness of Colchicine as an anti-inflammatory drug in the treatment of coronavirus disease 2019: Meta-analysis

Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics

Mortality Benefit of Convalescent Plasma in COVID-19 : A Systematic Review and Meta-Analysis

Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19

Efficacy and Safety of Convalescent Plasma for COVID-19: A Systematic Review and Meta-analysis

Early Convalescent Plasma for High-Risk Outpatients with Covid-19

Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials

Observational study of people infected with SARS-Cov-2, treated with amantadine

Amantadine inhibits sars-cov-2 in vitro

Pharmacological Recommendations for Delirium Associated With COVID-19

Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers

Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials

The mechanisms of action of Ivermectin against SARS-CoV-2: An evidence-based clinical review article

The pharmacokinetics and interactions of ivermectin in humans--a mini-review

Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus

Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials

Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India

Effectiveness and Safety of Niclosamaide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management: Randomized controlled clinical trial. medRxiv

Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients

Niclosamide Is a Proton Carrier and Targets Acidic Endosomes with Broad Antiviral Effects

Plausible mechanisms of Niclosamide as an antiviral agent against COVID-19

Broad-Spectrum , Patient-Adaptable Inhaled Niclosamide-Lysozyme Particles are Efficacious Against Coronaviruses in Lethal Murine Infection Models

Measures in COVID-19 Management : Randomized controlled clinical trial

KEVZARA (Sarilumab) Summary of Product Characteristics

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

Efficacy and safety of Xuanfei Baidu granules for treating COVID-19. Medicine (Baltimore)

Maxingshigan decoction for treating COVID-19

Efficacy and safety of Reyanning mixture combined with conventional Western medicine for treating COVID-19

Traditional Chinese medicine formula Xiaoqinglong decoction for cough caused by COVID-19

Efficacy and safety of Lianhua Qingwen in the treatment of patients with moderate COVID-19 infection

Efficacy and safety of Xiyanping for COVID-2019

Ascorbate prevents microvascular dysfunction in the skeletal muscle of the septic rat

Protective role of ascorbic acid against lipid peroxidation and myocardial injury

Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study

The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study

High-dose vitamin C intravenous infusion in the treatment of patients with COVID-19

Modulation of the immune response to respiratory viruses by vitamin D

Vitamin D supplementation and COVID-19 treatment: A systematic review and meta-analysis

Efficacy of zinc given as an adjunct to the treatment of severe pneumonia: A meta-analysis of randomized, double-blind and placebo-controlled trials

Zinc is an Antioxidant and Anti-Inflammatory Agent: Its Role in Human Health

Should we supplement zinc in COVID-19 patients? Evidence from meta-analysis. Polish Arch Intern Med

Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review

Dexamethasone in Hospitalized Patients

Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial

Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label

Healthcare disparities among anticoagulation therapies for severe COVID-19 patients in the multi-site VIRUS registry

Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients

Pharmacologie de l'aspirine

Rationales and uncertainties for aspirin use in COVID-19: a narrative review

Effects of Aspirin on Endothelial Function and Hypertension

Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in vitro study

Aspirin in patients admitted to hospital with COVID-19 ( RECOVERY ): a randomised , controlled , open-label , platform trial

Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease

Estatinas en COVID-19: ¿existe algún fundamento? Clínica e Investig en Arterioscler

Statins: Could an old friend help in the fight against COVID-19?

Pleiotropic effects of statins: A focus on cancer

In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19

Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients

Meta-analysis of Effect of Statins in Patients with COVID-19

Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19)

Are statins safe in patients with COVID-19?

A Proposed Framework and Timeline of the Spectrum of Disease Due to SARS-CoV-2 Infection

Long-COVID and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms

Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches

The Science Underlying COVID-19: Implications for the Cardiovascular System

Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia: JACC Focus Seminar

Cause-specific death in infected with SARS-CoV-2: more than just acute respiratory failure or thromboembolic events

Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients

Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: a narrative review

Respiratory follow-up of patients with COVID-19 pneumonia

COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection

Long covid-mechanisms, risk factors, and management

A systematic review of the use of opioids in the management of dyspnoea

COVID-19-The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection

Atrial Fibrillation: Diagnosis and Management NICE Guideline

National Institute for Health and Care Excellence

National Institute for Health and Care Excellence

Myocarditis in Clinical Practice

Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions

Sudden onset, acute loss of taste and smell in coronavirus disease 2019 (COVID-19): a systematic review

Does coronavirus affect the audio-vestibular system? A rapid systematic review

Older Patients With

Presenting to the Emergency Department

COVID-19: ICU delirium management during SARS-CoV-2 pandemic

Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study

Chemo brain -Diagnosis and treatment -Mayo Clinic

Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue

Renal artery thrombosis in COVID-19

Lung and kidney perfusion deficits diagnosed by dual-energy computed tomography in patients with COVID-19-related systemic microangiopathy

The Prevalence of Gastrointestinal Symptoms, Abnormal Liver Function, Digestive System Disease and Liver Disease in COVID-19 Infection: A Systematic Review and Meta-Analysis

Discovery and development of safe-in-man broad-spectrum antiviral agents

Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

Treatment of Coronavirus Disease 2019 Patients With Prolonged Postsymptomatic Viral Shedding With Leflunomide: A Single-center Randomized Controlled Clinical Trial

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial

Randomized Prospective Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized

Patients with Mild Hypoxemia

Remdesivir for the Treatment of Covid-19 -Final Report

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia: A Randomized Clinical Trial

Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis

Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv

Therapeutics and COVID-19: living guideline

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

Effectiveness of COVID-19 vaccines against variants of concern

Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials

Mortality Benefit of Convalescent Plasma in COVID-19: A Systematic Review and Meta-Analysis

Sarilumab in patients admitted to hospital with severe or critical COVID-19 : a randomised , double-blind , placebo-controlled , phase 3 trial